Drug
Anlotinib clinical trials
Also written AL3818 and ALTN.
- studies test it
- 260
- open now
- 104
- in phase 3
- 26
- first study started
- 2011
Keep track of what changes. Save the anlotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
- ALTN
- 2
Studies by the year they started
259 studies that test it; most in 2021 (38); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 7 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 23 |
| 2019 | 34 |
| 2020 | 30 |
| 2021 | 38 |
| 2022 | 24 |
| 2023 | 17 |
| 2024 | 26 |
| 2025 | 19 |
| 2026 | 26 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 34
- Phase 2
- 213
- Phase 3
- 26
- Phase 4
- 9
- No phase
- 13
What it is tested for
Each study’s main condition, where its own words name it.
- Sarcoma
- 12
Who runs them
Industry 49 · Other 211
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (40) · Sun Yat-sen University (16) · Fudan University (11) · Shanghai Chest Hospital (10) · The First Affiliated Hospital with Nanjing Medical University (10) · Tianjin Medical University Cancer Institute and Hospital (10) · Zhejiang Cancer Hospital (7) · Peking Union Medical College Hospital (6)
Often tested with
Tested in the same studies.
Benmelstobart (34) · Toripalimab (15) · Paclitaxel (15) · Penpulimab (13) · Sintilimab (12) · Albumin-Bound Paclitaxel (11) · Tislelizumab (10) · Cadonilimab (9)
Studies
Open first, then newest update. How each study uses anlotinib is read from its arms, and is right about nine times in ten.
Testing it · 260
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as Anlotinib
- Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT05296577Written as anlotinib and vinorelbine
- A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingPhase 2Sun Yat-sen UniversityNCT07863141Written as anlotinib + PD-1 inhibitor
- SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingPhase 2Fujian Cancer HospitalNCT07470840Written as Anlotinib
- Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07846267Written as Anlotinib
- Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingPhase 2Shanghai Chest HospitalNCT07830355Written as Anlotinib
- A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCRecruitingPhase 2Yantai Yuhuangding HospitalNCT07815223Written as Tislelizumab + Anlotinib
- A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingPhase 2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07562581Written as luvometinib + anlotinib
- The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Fudan UniversityNCT07780578Written as Anlotinib
- Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain MetastasesNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07745257Written as Anlotinib
- Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma ProtuberansNot yet recruitingPhase 2Yanjie Zhang, MDNCT07646080Written as Anlotinib
- Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above TreatmentNot yet recruitingPhase 2Yayi HeNCT07632209Written as Anlotinib
- Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNot applicableNanfang Hospital, Southern Medical UniversityNCT07627347Written as anlotinib+bevacizumab
- Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNot yet recruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07616141Written as Anlotinib + Epirubicin
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Anlotinib
- Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell CarcinomaNot yet recruitingPhase 2RenJi HospitalNCT07602101Written as TQB2450 + Anlotinib
- A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young AdultsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06761417Written as Anlotinib
- GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingPhase 3Sun Yat-sen UniversityNCT07540390Written as Anlotinib
- A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Yayi HeNCT07538271Written as Anlotinib
- Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingPhase 2Yayi HeNCT07538258Written as Anlotinib
See all 260 studies that test anlotinib →
Given in every arm · 14 — anlotinib is usual care beside what is tested
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Anlotinib
- A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM CancersNot yet recruitingPhase 1/2Advenchen Pharmaceuticals, LLC.NCT07811297Written as AL3818
- QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung CancerNot yet recruitingPhase 2/3Sun Yat-sen UniversityNCT07636226Written as Anlotinib
- Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue SarcomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07612098Written as Anlotinib
- Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract CancerRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07025174Written as Anlotinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Anlotinib
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT06699576Written as Anlotinib
- Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingPhase 2Fudan UniversityNCT05229003Written as Anlotinib
- Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLCCompletedPhase 1Hubei Cancer HospitalNCT05021328Written as Anlotinib
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedPhase 3AkesoNCT03866980Written as Anlotinib
- Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast CancerStatus unknownPhase 2Chinese Academy of Medical SciencesNCT05089643Written as Anlotinib
- A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04273815Written as Anlotinib
- Phase I Study of the Combination of Anlotinib With Pemetrexed or DocetaxelStatus unknownNot applicableFujian Cancer HospitalNCT03566576Written as Anlotinib
- Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCStatus unknownPhase 1/2West China HospitalNCT03201146Written as AP or AC